The Tumey lab has developed two IP-enabled technologies for next generation antibody-drug-conjugate (ADC) designs. In order to de-risk these technology platforms and position them for licensing, we propose three specific aims: 1) Understand the pharmacokinetics of these ADCs in rodents; 2) Establish efficacy in an immune-competent mouse cancer model; and 3) Assess the potency in human-derived immune cell assays to establish translational potential.
Join the National NSF ART Network – Submit the Membership Request Form
